Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway
Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Katharina Schmid(Medical University of Vienna), Michael Grusch(Comprehensive Cancer Center Vienna), Wolfgang Sieghart(Atitus Educação), Walter Berger(Comprehensive Cancer Center Vienna), Oxana Komina(Comprehensive Cancer Center Vienna), Hubert Hayden(Medical University of Vienna), Andreas Lackner(Medical University of Vienna), Andrea Haitel(University of Vienna), Christine Pirker(Comprehensive Cancer Center Vienna), Józefa Węsierska‐Gądek(Comprehensive Cancer Center Vienna), Martin Filipits(University of Vienna)
Cited by 31
Related Papers
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303